Orphan Synergy Europe - Pharma SA Aktie

5,86 EUR +0,06 EUR +1,03 %

26.09.2025

BMN

4,40 EUR +0,02 EUR +0,34 %

29.12.2023

LSE

Orphan Synergy Europe - Pharma SA jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.135,05 Mio. EUR

KGV4,18Div. Rendite0,00%

WKNA14QXP

ISINFR0012127173

SymbolORPOF

Orphan Synergy Europe - Pharma SA Aktien News

Sortieren:Datum Meistgelesen

11.06.25GlobeNewswireADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025

09.06.25GlobeNewswireUPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING

04.06.25GlobeNewswireOse Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025

WerbungOrphan Synergy Europe - Pharma SA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

04.06.25GlobeNewswireOSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology

02.06.25GlobeNewswireOSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer

23.05.25GlobeNewswireOSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials

21.05.25GlobeNewswireOSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies

05.05.25GlobeNewswireOSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab

30.04.25GlobeNewswireImmuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025

23.04.25GlobeNewswireOSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025

09.04.25GlobeNewswireOSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025

03.04.25GlobeNewswireOSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025

26.03.25GlobeNewswireOSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

11.03.25GlobeNewswireOSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

06.03.25GlobeNewswireOSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

24.02.25GlobeNewswireOSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

20.02.25GlobeNewswireOSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

29.01.25GlobeNewswireOSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

28.01.25GlobeNewswireOSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

13.01.25GlobeNewswireOSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

18.12.24GlobeNewswireOSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO

11.12.24GlobeNewswireOSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

02.12.24GlobeNewswireOSE Immunotherapeutics Strengthens Leadership and Executive Committee

04.11.24GlobeNewswireOSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

17.10.24GlobeNewswireOSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

26.09.24GlobeNewswireOSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

10.09.24GlobeNewswireOSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer

24.07.24GlobeNewswireOSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis

03.07.24GlobeNewswireBoehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

01.07.24GlobeNewswireOSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

24.06.24GlobeNewswireOSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

20.06.24GlobeNewswireOSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)

19.06.24GlobeNewswireOSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth

12.06.24GlobeNewswireOSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse

05.06.24GlobeNewswireOSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

30.05.24GlobeNewswireOSE Immunotherapeutics Provides Business and Corporate Update

22.05.24GlobeNewswireOSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

16.04.24GlobeNewswireOSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective

10.04.24GlobeNewswireOSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer

02.04.24GlobeNewswireOSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology

Orphan Synergy Europe - Pharma SA News

Orphan Synergy Europe - Pharma SA News: auf dieser Seite finden Sie alle Orphan Synergy Europe - Pharma SA News und Nachrichten zur Orphan Synergy Europe - Pharma SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Orphan Synergy Europe - Pharma SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Orphan Synergy Europe - Pharma SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.